I am Paul Conyngham, Rosie’s owner and the founder of Gamgee. In 2024, Rosie was diagnosed with mast cell cancer. Surgery, chemotherapy and immunotherapy did not stop the cancer from progressing, and her vets gave her months to live.
I am not a biologist. I have spent 17 years in machine learning. So I did what I know how to do. I started researching, using AI to map the specific mutations driving her cancer, design a personalised mRNA vaccine targeting those mutations, and coordinate its manufacture with researchers at UNSW.
In December 2025, Rosie received her first injection after a 14-hour drive to Queensland.
Three months later, the tumours on her legs had significantly reduced and she remained alive beyond the original timeline she had been given.
Rosie’s case led me to found Gamgee. The underlying tools already exist: genomic sequencing, protein modelling and mRNA synthesis. What I built for Rosie was not new science. It was a new route to access.
I should not have been the only person who could do this. A background in machine learning and months of obsessive research should not be the price of admission. Every dog owner facing this diagnosis deserves the same options I had, without having to become a citizen scientist to get them.
The first end-to-end personalised cancer treatment protocol for dogs.
Together with collaborators at UNSW, the University of Queensland and the Garvan Institute, we have built the end-to-end workflow and are now evaluating it through an Australian trial.
We are currently running a trial in Australia. Registrations of interest are open worldwide. Every case matters, and Australia is where we start.